NCT06363461
Study of TDM-180935 in Atopic Dermatitis Patients
A Randomized, Vehicle-Controlled, Parallel Group Study of Topical TDM-180935 to Evaluate the Preliminary Efficacy, Safety, Tolerability, and Pharmacokinetics in Atopic Dermatitis Patients
Technoderma Medicines Inc.·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Atopic Dermatitis
- Drug/Device/Intervention
- TDM-180935 topical ointment 1.0%
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Technoderma Medicines Inc.
- Location
- Rolling Meadows,Covington,New Brighton,Anderson,Austin,College Station,Norfolk, United States of America
Timeline & enrollment
- Phase
- Phase 2
- Start date
- Apr 13, 2024
- End date
- Oct 31, 2024
- Enrollment
- 24 participants
Primary outcome
Change in m-EASI (modified Eczema Area and Severity Index) score
Summary
Randomized, Vehicle-controlled, Parallel Group Study of TDM-180935 in Atopic Dermatitis
 Patients
ICD-10 classifications
Atopic dermatitisAtopic dermatitis, unspecifiedOther atopic dermatitisAcute atopic conjunctivitisAllergic contact dermatitis
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06363461
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06363461 through Pure Global AI's free database. This Phase 2 trial is sponsored by Technoderma Medicines Inc. and is currently Recruiting. The study focuses on Atopic Dermatitis. Target enrollment is 24 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.